# A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059)

> **NCT02335411** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 318 (actual)

## Conditions studied

- Gastric Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma

## Interventions

- **BIOLOGICAL:** pembrolizumab
- **DRUG:** cisplatin
- **DRUG:** 5-FU
- **DRUG:** capecitabine

## Key facts

- **NCT ID:** NCT02335411
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02-03
- **Primary completion:** 2021-07-23
- **Final completion:** 2021-07-23
- **Target enrollment:** 318 (ACTUAL)
- **Last updated:** 2022-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02335411

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02335411, "A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02335411. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*